Castle Biosciences, Inc.
NASDAQ:CSTL
31.8 (USD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Castle Biosciences, Inc. |
Symbool | CSTL |
Munteenheid | USD |
Prijs | 31.8 |
Beurswaarde | 890,632,140 |
Dividendpercentage | 0% |
52-weken bereik | 16.965 - 35.84 |
Industrie | Diagnostics & Research |
Sector | Healthcare |
CEO | Mr. Derek J. Maetzold |
Website | https://castlebiosciences.com |
An error occurred while fetching data.
Over Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)